MetaCap

Monte Rosa Therapeutics Inc. (GLUE)

NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

8.64-0.27 (-3.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GLUE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$738.29M
EPS (TTM)
-$1.39
52-week range
8.48 – 25.77
Day range
8.48 – 9.04
Volume / Avg
2.52M / 1.37M
Beta
—

52-week range

$8.48$25.77

GLUE stock today

Monte Rosa Therapeutics (GLUE) closed at $8.64 on Nov 20, down 3.03% (-$0.27), versus the S&P 500's 3.70% decline. Shares are 66.5% below their 52-week high of $25.77, set on Jan 8, 2026 and 1.9% above the 52-week low of $8.48, near the bottom of the past year's range. GLUE is down 44.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.2%.

Monte Rosa Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Monte Rosa Therapeutics

Company profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Markus Warmuth M.D.
Headquarters
Boston, MA
Employees
185
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Monte Rosa Therapeutics generated $123.7 million in revenue, up 63.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Monte Rosa Therapeutics reported a net loss of $38.6 million, compared with a loss of $72.7 million a year earlier. Operating margin was -43.8%.

Monte Rosa Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$123.67M$75.62M$0——
Growth+63.54%————
Net income$-38.60M$-72.70M$-135.35M$-108.50M$-73.96M
EPS (diluted)$-0.46$-0.98$-2.63$-2.30$-2.96

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$25.38+193.75%

  • Strong buy 2
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $15.00High $37.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.03 vs $-0.10
Surprise
+130.00%

GLUE news

All GLUE news

Monte Rosa Therapeutics peers

Health Care sector
GLUE peer companies
CompanyPrice% ChgMarket capCompare
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs GLUE
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs GLUE
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs GLUE
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs GLUE
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs GLUE
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs GLUE
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs GLUE
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs GLUE

Indexes, lists and sector

Monte Rosa Therapeutics stock FAQ

What is Monte Rosa Therapeutics's stock price today?

GLUE last traded at $8.64 as of Nov 20, 4:00 PM EST, down 3.03% on the day. Prices are delayed at least 15 minutes.

Who is Monte Rosa Therapeutics's CEO?

Dr. Markus Warmuth M.D. is the chief executive officer of Monte Rosa Therapeutics Inc., which has about 185 employees.

What is the GLUE 52-week high?

The 52-week high for GLUE is $25.77 and the 52-week low is $8.48. The stock is currently 66.5% below its high.

Compare GLUE